DAX22.288 -0,1%ESt505.475 +0,3%Top 10 Crypto14,64 -1,8%Dow43.428 -1,7%Nas19.524 -2,2%Bitcoin92.383 +0,6%Euro1,0461 ±0,0%Öl74,25 -3,1%Gold2.936 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Palantir A2QA4J Tesla A1CX3T BYD A0M4W9 Alibaba A117ME Siemens Energy ENER6Y Mercedes-Benz Group (ex Daimler) 710000 Amazon 906866 Xiaomi A2JNY1 RENK RENK73 Infineon 623100 Bayer BAY001 Deutsche Telekom 555750 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht etwas schwächer ins Wochenende -- Wall Street rot -- Rivian kann Verluste eindämmen -- Newmont schreibt wieder schwarze Zahlen -- Palantir, Nissan, Rheinmetall, thyssenkrupp im Fokus
Top News
Aktueller Marktbericht zu Bitcoin & Co. Aktueller Marktbericht zu Bitcoin & Co.
Berkshire Hathaway-Aktie: Holding von Starinvestor Warren Buffett mit Gewinnrückgang Berkshire Hathaway-Aktie: Holding von Starinvestor Warren Buffett mit Gewinnrückgang
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Nur bis 28. Februar: Depot bei finanzen.net ZERO eröffnen und attraktiven Neukunden­bonus erhalten. Jetzt informieren!

Novo Nordisk Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
83,63 EUR +3,02 EUR +3,75 %
FSE
84,36 EUR +4,80 EUR +6,03 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.374,86 Mrd. EUR

KGV27,53Div. Rendite1,83%

WKNA3EU6F

ISINDK0062498333

SymbolNONOF

Novo Nordisk Aktien News

DatumMeistgelesen
GlobeNewswireNovo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
GlobeNewswireNovo Nordisk A/S – Share repurchase programme
GlobeNewswireNovo Nordisk A/S – Share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
GlobeNewswireNovo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S – Share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S – Share repurchase programme
GlobeNewswireEuropean regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
GlobeNewswireNovo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in th
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireTrading in Novo Nordisk shares by board members, executives and associated persons
Wer­bung

Novo Nordisk News

Novo Nordisk News: auf dieser Seite finden Sie alle Novo Nordisk News und Nachrichten zur Novo Nordisk Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.